$NTLA #ATTR News: Intellia’s investigational #CRISPR treatment for #transthyretinamyloidosis, NTLA-2001, receives European Union Orphan Drug Designation. Click here to read the full details: https://t.co/afKb7it4xH #genomeediting https://t.co/d65TrKVaJE